Treatment Patterns in Surgically Resected NSCLC Since the Introduction of ImmunoOncology Agents
07:30am - 03:35pm EDT - April 5, 2024
07:30am - 03:35pm EDT - April 5, 2024
Abstract: JNCCN23-0677 https://jnccn.org/view/journal...
Author(s):
- Dr. Daniel Simmons, PharmD, MS, Director of Oncology Outcomes Research, AstraZeneca
Tags: Member Institution Outcomes and Health Services Research
| Display Label | Action |
|---|---|
| Treatment Patterns in Surgically Resected NSCLC Since the Introduction of Immuno-Oncology Agents Final Poster 2.pdf | Download Handout |